Organ and cell transplants can save lives. However, they often require a trade-off.

To prevent rejection, patients typically take powerful immunosuppressive drugs. While those medications protect transplanted tissues, they also weaken the immune system and increase the risk of infection.

Researchers have long searched for a better solution.

Now, a team at the University of California, San Francisco (UCSF) has developed a promising approach using specially engineered stem cells that may avoid immune rejection altogether.

Engineering “Universal” Stem Cells

The researchers created what they call HIP cells, a modified form of induced pluripotent stem cells (iPSCs).

Scientists generate iPSCs by reprogramming adult cells into stem cells that can become many different cell types.

The UCSF team took that concept a step further.

Using gene editing, they engineered the cells to avoid detection by the immune system. The goal was to create a “universal” stem cell that could work in many different recipients without triggering rejection.

If successful, the approach could eliminate one of the biggest barriers to cell-based therapies.

Avoiding Immune Rejection Without Immunosuppression

To test the concept, researchers transplanted HIP-derived cells into mouse models of several serious diseases:

• Peripheral artery disease
• Chronic obstructive pulmonary disease (COPD)
• Heart failure

The results were encouraging.

Expanding Access to Regenerative Medicine

Study author Dr. Tobias Deuse said the engineered cells successfully avoided immune rejection across different genetic backgrounds.

“We showed that immune-engineered HIP cells reliably evade immune rejection in mice with different tissue types,” he said.

Importantly, the cells maintained that immune-evasive ability even in diseased tissues and without immunosuppressive medications.

That combination could significantly simplify future cell therapies.

Researchers would no longer need to create customized treatments for every patient or rely on long-term immune suppression.

A Potential Path Toward More Affordable Therapies

The technology could offer another important advantage: lower cost.

Today, many advanced cell therapies require individualized manufacturing, complex logistics, and extensive clinical monitoring.

Universal donor cells could streamline production and make treatments more scalable.

“In order for a therapeutic to have a broad impact, it needs to be affordable,” said Deuse.

He noted that reducing manufacturing complexity could help expand patient access and bring regenerative medicine to larger populations.

Looking Ahead

The work remains in the preclinical stage, and researchers must still demonstrate safety and effectiveness in humans.

Even so, the study highlights an exciting possibility for the future of transplantation and regenerative medicine.

If scientists can reliably create immune-evasive stem cells, they may eventually produce off-the-shelf therapies for a wide range of diseases.

Such treatments could eliminate the need for donor matching, reduce dependence on immunosuppressive drugs, and make regenerative therapies more accessible and affordable.

For patients awaiting transplants or cell-based treatments, that would represent a major advance.